Structure-activity Relationships of Substituted 1-pyridyl-2-phenyl-1,2-ethanediones: Potent, Selective Carboxylesterase Inhibitors
Overview
Authors
Affiliations
Inhibition of intestinal carboxylesterases may allow modification of the pharmacokinetics/pharmacodynamic profile of existing drugs by altering half-life or toxicity. Since previously identified diarylethane-1,2-dione inhibitors are decidedly hydrophobic, a modified dione scaffold was designed and elaborated into a >300 member library, which was subsequently screened to establish the SAR for esterase inhibition. This allowed the identification of single digit nanomolar hiCE inhibitors that showed improvement in selectivity and measured solubility.
Kong L, Meng J, Tian W, Liu J, Hu X, Jiang Z ACS Omega. 2022; 7(1):1380-1394.
PMID: 35036799 PMC: 8757360. DOI: 10.1021/acsomega.1c06017.
Nandwana N, Patel O, Srivathsa M, Kumar A ACS Omega. 2019; 4(6):10140-10150.
PMID: 31460106 PMC: 6648449. DOI: 10.1021/acsomega.9b00716.
Yu Y, Kong R, Cao H, Yin Z, Liu J, Nan X Oncotarget. 2018; 9(46):27958-27973.
PMID: 29963254 PMC: 6021345. DOI: 10.18632/oncotarget.24563.
Human carboxylesterase 2: Studies on the role of glycosylation for enzymatic activity.
Alves M, Lamego J, Bandeiras T, Castro R, Tomas H, Coroadinha A Biochem Biophys Rep. 2017; 5:105-110.
PMID: 28955811 PMC: 5598387. DOI: 10.1016/j.bbrep.2015.11.018.
Argikar U, Potter P, Hutzler J, Marathe P AAPS J. 2016; 18(6):1391-1405.
PMID: 27495117 PMC: 5354079. DOI: 10.1208/s12248-016-9962-6.